CN108883170A - 可程序化的通用细胞受体及其使用方法 - Google Patents

可程序化的通用细胞受体及其使用方法 Download PDF

Info

Publication number
CN108883170A
CN108883170A CN201680076271.2A CN201680076271A CN108883170A CN 108883170 A CN108883170 A CN 108883170A CN 201680076271 A CN201680076271 A CN 201680076271A CN 108883170 A CN108883170 A CN 108883170A
Authority
CN
China
Prior art keywords
cell
antibody
catalytic
pucr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680076271.2A
Other languages
English (en)
Chinese (zh)
Inventor
贡纳·乔格·弗洛里斯·考夫曼
Y·福
张延良
詹姆斯·T·帕特森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of CN108883170A publication Critical patent/CN108883170A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4276—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680076271.2A 2015-10-23 2016-10-24 可程序化的通用细胞受体及其使用方法 Pending CN108883170A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562245978P 2015-10-23 2015-10-23
US62/245,978 2015-10-23
US201662382691P 2016-09-01 2016-09-01
US62/382,691 2016-09-01
PCT/US2016/058429 WO2017070654A1 (en) 2015-10-23 2016-10-24 Programmable universal cell receptors and methods of using the same

Publications (1)

Publication Number Publication Date
CN108883170A true CN108883170A (zh) 2018-11-23

Family

ID=58558187

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680076271.2A Pending CN108883170A (zh) 2015-10-23 2016-10-24 可程序化的通用细胞受体及其使用方法

Country Status (11)

Country Link
US (1) US20170112878A1 (cg-RX-API-DMAC10.html)
EP (1) EP3365016A4 (cg-RX-API-DMAC10.html)
JP (1) JP2018537076A (cg-RX-API-DMAC10.html)
KR (1) KR20180091820A (cg-RX-API-DMAC10.html)
CN (1) CN108883170A (cg-RX-API-DMAC10.html)
AU (1) AU2016341321A1 (cg-RX-API-DMAC10.html)
CA (1) CA3002774A1 (cg-RX-API-DMAC10.html)
EA (1) EA201890941A1 (cg-RX-API-DMAC10.html)
TW (1) TW201726914A (cg-RX-API-DMAC10.html)
UY (1) UY36961A (cg-RX-API-DMAC10.html)
WO (1) WO2017070654A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2019010201A1 (en) * 2017-07-03 2019-01-10 Yale University REGULATED SMALL MOLECULE ADAPTER
KR20200076732A (ko) 2017-11-03 2020-06-29 소렌토 쎄라퓨틱스, 인코포레이티드 Cd38-지시된 키메라 항원 수용체 작제물
SG11202008568WA (en) 2018-03-09 2020-10-29 Sorrento Therapeutics Inc Dimeric antigen receptors (dar)
CN114846030A (zh) * 2019-10-23 2022-08-02 佛罗里达大学研究基金会公司 催化抗体38c2的新型缀合化学
EP4114415A1 (en) * 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
CN116601174A (zh) * 2020-10-12 2023-08-15 索伦托药业有限公司 Cd19定向的嵌合抗原受体构建体
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
US20240197881A1 (en) * 2021-04-23 2024-06-20 Sorrento Therapeutics, Inc. Dimeric Antigen Receptors (DARs) that Bind GD2
WO2023154708A2 (en) * 2022-02-10 2023-08-17 The Scripps Research Institute Car-t therapies targeted via covalently bonded adapters

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096933A (zh) * 2010-07-12 2013-05-08 CovX科技爱尔兰有限公司 多功能抗体缀合物
CN103492406A (zh) * 2010-12-09 2014-01-01 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268488B1 (en) * 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
CA2515100A1 (en) * 2003-02-06 2004-08-19 Micromet Ag Trimeric polypeptide construct to induce an enduring t cell response
DK2187965T3 (da) * 2007-08-17 2020-01-20 Purdue Research Foundation Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse
JP5934099B2 (ja) * 2009-10-01 2016-06-15 アメリカ合衆国 抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
EP3459560B1 (en) * 2011-04-08 2021-02-24 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
US9708384B2 (en) * 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2017070654A1 (en) * 2015-10-23 2017-04-27 Sorrento Therapeutics, Inc. Programmable universal cell receptors and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103096933A (zh) * 2010-07-12 2013-05-08 CovX科技爱尔兰有限公司 多功能抗体缀合物
CN103492406A (zh) * 2010-12-09 2014-01-01 宾夕法尼亚大学董事会 嵌合抗原受体-修饰的t细胞治疗癌症的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPH RADER ET AL: "Chemically programmed monoclonal antibodies for cancer therapy: Adaptor immunotherapy based on a covalent antibody catalyst", 《PNAS》 *
RAJIB KUMAR GOSWAMI ET AL: "Multiple catalytic aldolase antibodies suitable for chemical programming", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Also Published As

Publication number Publication date
TW201726914A (zh) 2017-08-01
CA3002774A1 (en) 2017-04-27
EA201890941A1 (ru) 2018-11-30
EP3365016A4 (en) 2019-07-17
UY36961A (es) 2017-05-31
KR20180091820A (ko) 2018-08-16
AU2016341321A1 (en) 2018-06-07
US20170112878A1 (en) 2017-04-27
EP3365016A1 (en) 2018-08-29
WO2017070654A1 (en) 2017-04-27
WO2017070654A8 (en) 2017-06-01
JP2018537076A (ja) 2018-12-20

Similar Documents

Publication Publication Date Title
US20170112878A1 (en) Programmable universal cell receptors and method of using the same
JP7836847B2 (ja) 二重特異性キメラ抗原受容体およびその治療的使用
US20240374748A1 (en) Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
JP6632073B2 (ja) キメラ抗原受容体
JP6613304B2 (ja) 抗ｃｄ２７６抗体（ｂ７ｈ３）
KR20220169488A (ko) 신규한 항원 결합 도메인 및 이를 포함하는 합성 항원 수용체
JP2022524507A (ja) 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法
JP2022502043A (ja) 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
CN111315872A (zh) 用于癌症的过继性细胞疗法的组合物和方法
US20250297022A1 (en) Engineered switches for immune cell activity and methods of use thereof
TW202144396A (zh) 抑制性嵌合受體架構
JP2025540340A (ja) キメラ抗原受容体
US20230372484A1 (en) Chimeric antigen receptors for treatment of cancer
JP2023542230A (ja) Ｐｒａｍｅ特異的ｔ細胞受容体およびその使用
WO2025158420A1 (en) Methods and composition for inducing activation and dna expression in t-cells
WO2024081824A2 (en) Synthetic intermediates for universal chimeric antigen receptor immune cell therapies
US20210275586A1 (en) Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targetting cancer cells
US20250353931A1 (en) Multi-specific reagent for targeted delivery of lipid nanoparticles
WO2025255266A1 (en) Engineered polypeptides for immune cell activation
US20250186494A1 (en) Car-t therapies targeted via covalently bonded adapters
WO2023133424A2 (en) Compositions and methods for tcr reprogramming using fusion proteins and anti-pd-1 fusion peptides
JP2025526383A (ja) 阻害性キメラ受容体アーキテクチャ
TW202535941A (zh) 具有特製藥物對抗體比之抗體-藥物結合物
WO2025218621A1 (zh) 靶向muc1的抗原结合蛋白
WO2025252993A1 (en) Chimeric antigen receptor targeting glioma-associated antigens

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123